Treatment of psoriatic arthritis with traditional DMARD’s and novel therapies: approaches and recommendations

ABSTRACT

Introduction: Recent advances in the therapeutics of psoriatic arthritis (PsA) have provided more options to clinicians managing PsA. The purpose of this review is to update the reader on treatment options for PsA using conventional synthetic disease modifying agents (csDMARDs) and novel therapies including tumour necrosis factor alpha inhibitors, interleukin 12/23 inhibitor (ustekinumab), the interleukin 17 antagonists including secukinumab, brodalumab, ixekizumab, and the phosphodiesterase-4 inhibitor, apremilast.

Areas covered: We reviewed published articles on the treatment of PsA. Our main sources of data included treatment recommendations, registry studies, systematic literature reviews, major randomised controlled trials for more recently approved drugs, and abstracts from the American College of Rheumatology and EULAR meetings.

Expert commentary: An overview of the evidence for the use of various pharmacotherapeutic agents for treatment of this heterogeneous disease was compiled. Treatment options for the various domains of PsA are also discussed.

KEYWORDS:

• Anti-tumour necrosis factor alpha inhibitors
• apremilast
• disease modifying anti-rheumatic drugs
• interleukin-12/23 inhibitors
• interleukin-17 inhibitors
• non-steroidal anti-inflammatory drugs
• psoriasis
• spondyloarthritis

Declaration of interest

AB Maharaj has received honoraria for consultancy from Abbvie, Pfizer, Janssen and AstraZeneca. AB Maharaj has also received speaker fees from Abbvie, Pfizer, Janssen, AstraZeneca and Novartis. V Chandran has received honoraria for consultancy from Abbvie, Amgen, Celgene, Janssen, Novartis and UCB. V Chandran has received research grants from Abbvie; spouse is an employee of Eli Lilly. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was not funded.